92.50

0.05% -0.05

After Hours: 92.50

Blueprint Medicines Corp (BPMC)

Overview News Price History Option Chain Financials Why BPMC Down? Discussions Forecast

Blueprint Medicines Corp stock is traded at $92.50, with a volume of 654.95K. It is down -0.05% in the last 24 hours and down -3.18% over the past month. Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Previous Close:

$92.55

Open:

$92.33

24h Volume:

654.95K

Relative Volume:

0.97

Market Cap:

$5.70B

Revenue:

$362.80M

Net Income/Loss:

$-205.49M

P/E Ratio:

-10.07

EPS:

-9.19

Net Cash Flow:

$-347.59M

1W Performance:

+2.71%

1M Performance:

-3.18%

6M Performance:

-2.49%

1Y Performance:

+84.19%

1-Day Range:

$89.51

$92.73

1-Week Range:

$86.92

$94.69

52-Week Range:

$43.89

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name

Blueprint Medicines Corp

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-374-7580

Address

45 SIDNEY STREET, CAMBRIDGE, MA

Employee

655

Twitter

@BlueprintMeds

Next Earnings Date

2024-10-24

Latest SEC Filings

BPMC's Discussions on Twitter

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform
Aug-21-23	Reiterated	Needham	Buy
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Needham	Buy
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy
Jul-08-22	Initiated	Oppenheimer	Outperform
Jun-27-22	Initiated	Wells Fargo	Underweight
Jun-10-22	Downgrade	Citigroup	Neutral → Sell
Jun-01-22	Upgrade	Jefferies	Hold → Buy
Mar-01-22	Initiated	Citigroup	Neutral
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jan-25-22	Upgrade	Stifel	Hold → Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Sep-30-21	Resumed	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Hold
Nov-02-20	Reiterated	H.C. Wainwright	Buy
Nov-02-20	Downgrade	Jefferies	Buy → Hold
Oct-30-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-15-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Equal Weight
Mar-17-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Nov-06-19	Upgrade	Raymond James	Outperform → Strong Buy
Oct-22-19	Initiated	JMP Securities	Mkt Outperform
Oct-03-19	Initiated	H.C. Wainwright	Buy
Sep-12-19	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-29-19	Initiated	Piper Jaffray	Neutral
Aug-15-19	Resumed	Raymond James	Mkt Perform
Jul-18-19	Initiated	Deutsche Bank	Buy
May-23-19	Resumed	Goldman	Buy
Apr-03-19	Initiated	Morgan Stanley	Overweight
Sep-25-18	Initiated	Leerink Partners	Outperform
Dec-11-17	Reiterated	Goldman	Buy

View All

Blueprint Medicines Corp Stock (BPMC) Latest News

01:36 AM

An Analysis of Blueprint Medicines Corp (BPMC)’s Potential Price Growth - Knox Daily

01:36 AM

Sep 29, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Update - MarketBeat

Sep 29, 2024

Hsbc Holdings PLC Acquires Shares of 9,964 Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Sep 29, 2024

Sep 28, 2024

Susquehanna Portfolio Strategies LLC Sells 57,540 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Sep 28, 2024

Sep 27, 2024

Wall Street SWOT: Blueprint Medicines stock rides Ayvakit wave amid pipeline promise - Investing.com

Sep 27, 2024

Analysts Set Blueprint Medicines Co. (NASDAQ:BPMC) Price Target at $120.00 - MarketBeat

Sep 27, 2024

Sep 26, 2024

Point72 Europe London LLP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Sep 26, 2024

Sep 24, 2024

Its Stock Has Paid Off Big Time For Blueprint Medicines Corp - SETE News

Sep 24, 2024

Integral Health Asset Management LLC Buys 130,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Sep 24, 2024

Sep 20, 2024

Can you now get a good deal on Blueprint Medicines Corp’s shares? - US Post News

Sep 20, 2024

Q2 2026 Earnings Estimate for Blueprint Medicines Co. (NASDAQ:BPMC) Issued By Zacks Research - MarketBeat

Sep 20, 2024

Sep 19, 2024

Stifel maintains Buy on Blueprint Medicines, target at $155 - Investing.com

Sep 19, 2024

Director Albers Jeffrey W. sold 19,702 shares of Blueprint Medicines Corp [BPMC] - Knox Daily

Sep 19, 2024